Mariner
CRL icon

Mariner’s Charles River Laboratories CRL Stock Holding History

Mariner’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$996K Sell
5,776
-5,075
-47% -$941K ﹤0.01% 1975
2025
Q4 		$2.17M Sell
10,851
-7,505
-41% -$1.36M ﹤0.01% 1448
2025
Q3 		$2.87M Buy
18,356
+1,492
+9% +$237K ﹤0.01% 1214
2025
Q2 		$2.56M Sell
16,864
-1,705
-9% -$227K ﹤0.01% 1187
2025
Q1 		$2.8M Sell
18,569
-1,079
-5% -$181K ﹤0.01% 1064
2024
Q4 		$3.63M Sell
19,648
-427
-2% -$82.3K 0.01% 922
2024
Q3 		$3.95M Buy
20,075
+259
+1% +$53.8K 0.01% 875
2024
Q2 		$4.09M Buy
19,816
+3,944
+25% +$894K 0.01% 804
2024
Q1 		$4.3M Buy
15,872
+237
+2% +$56.6K 0.01% 789
2023
Q4 		$3.7M Buy
15,635
+6,071
+63% +$1.19M 0.01% 799
2023
Q3 		$1.87M Sell
9,564
-64
-0.7% -$13.1K 0.01% 1002
2023
Q2 		$2.02M Sell
9,628
-652
-6% -$130K 0.01% 972
2023
Q1 		$2.07M Sell
10,280
-1,147
-10% -$260K 0.01% 938
2022
Q4 		$2.49M Buy
11,427
+1,976
+21% +$432K 0.01% 834
2022
Q3 		$1.86M Buy
+9,451
New +$2.04M 0.01% 802

Other funds holding CRL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Mariner's CRL Position: Q1 2026 in Review

Mariner reduced its Charles River Laboratories (CRL) stake by 47% in Q1 2026, selling an estimated $941K and leaving 5,776 shares worth $996K. The position accounts for ﹤0.01% of the portfolio, ranked #1975.

Mariner first reported a position in CRL in Q3 2022 and has held it in 15 quarters since. The position peaked at $4.3M in Q1 2024. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • Mariner held 5,776 shares of Charles River Laboratories worth $996K as of Q1 2026.
  • Mariner sold 5,075 Charles River Laboratories shares in Q1 2026, an estimated $941K.
  • Charles River Laboratories made up ﹤0.01% of Mariner's portfolio in Q1 2026, its #1975 holding.
  • Mariner first reported a position in Charles River Laboratories in Q3 2022 and has held it in 15 quarters since.
  • Mariner's Charles River Laboratories position peaked at $4.3M in Q1 2024.
  • 557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Mariner's 13F filing for Q1 2026, filed 13 May 2026.